Search Results for "phototherapy"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for phototherapy. Results 31 to 32 of 32 total matches.
Treatment of Onychomycosis
The Medical Letter on Drugs and Therapeutics • Oct 18, 2021 (Issue 1635)
in patients receiving phototherapy.
CHILDREN — Onychomycosis is less common in
children than in adults.35 ...
Onychomycosis is caused most commonly by
Trichophyton rubrum or T. mentagrophytes. About
10% of all persons worldwide and 40% of those ≥60
years old are believed to have the disease. Risk
factors include older age, diabetes, poor peripheral
circulation, smoking, HIV infection, psoriasis, and
immunosuppression. Left untreated, onychomycosis
can cause nail plate destruction, ingrown nails, and
(particularly in patients with diabetes) secondary
infections. Guidelines on treatment of onychomycosis
have been published.
Three Drugs for Atopic Dermatitis (Adbry, Cibinqo, and Rinvoq)
The Medical Letter on Drugs and Therapeutics • Apr 03, 2023 (Issue 1673)
that is inadequately controlled
with topical drugs and/or phototherapy.6 Dupilumab
has significantly improved skin ...
The subcutaneously injected interleukin-13 (IL-13)
antagonist tralokinumab-ldrm (Adbry – Leo) and
the oral Janus kinase (JAK) inhibitors abrocitinib
(Cibinqo – Pfizer) and upadacitinib (Rinvoq – Abbvie)
have been approved by the FDA for treatment of
moderate to severe atopic dermatitis.
Med Lett Drugs Ther. 2023 Apr 3;65(1673):51-5 doi:10.58347/tml.2023.1673b | Show Introduction Hide Introduction